List of articles in "Drug" category - Page 129

Sabcomeline (Memric; SB-202026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer’s disease. It made it to phase III clinical trials before being […]

Milameline (CI-979 PD-129409 RU-35926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer’s disease but produced poor results in […]

Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist that was under investigation for the treatment of Alzheimer’s disease but produced poor results in clinical trials and […]

Profadol (CI-572) is an opioid analgesic which was developed in the 1960s by Parke-Davis. It acts as a mixed agonist-antagonist of the μ-opioid receptor. The analgetic potency is about the […]

Didesmethylcitalopram is an active metabolite of the antidepressant drug citalopram (racemic). Didesmethylescitalopram is an active metabolite of the antidepressant escitalopram the S-enantiomer of citalopram. Like citalopram and escitalopram didesmethyl(es)citalopram functions […]

Ladostigil (TV-3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer’s disease Lewy body disease and Parkinson’s disease. It acts as a reversible acetylcholinesterase […]

25-Dimethoxy-4-fluoroamphetamine (DOF) is a psychedelic drug of the phenethylamine and amphetamine classes. Alexander Shulgin briefly describes DOF in his book PiHKAL: Animal studies that have compared DOF to the highly […]

Amfecloral (INN) also known as amphecloral (USAN) is a stimulant drug of the phenethylamine and amphetamine chemical classes that was used as an appetite suppressant under the trade name Acutran […]

Alniditan is a 5-HT1D receptor agonist with migraine-preventative effects.

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis inflammatory bowel disease and multiple sclerosis. As of 2011 drug development for […]